 Joshua Thurman
Concepts (630)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 45 | 2025 | 327 | 11.900 |
Why?
| | Complement Activation | 66 | 2025 | 415 | 11.050 |
Why?
| | Kidney Diseases | 25 | 2024 | 408 | 8.920 |
Why?
| | Complement Pathway, Alternative | 36 | 2025 | 122 | 6.660 |
Why?
| | Complement Factor H | 19 | 2025 | 80 | 6.070 |
Why?
| | Kidney Glomerulus | 17 | 2025 | 119 | 5.120 |
Why?
| | Complement Inactivating Agents | 16 | 2025 | 63 | 5.050 |
Why?
| | Kidney | 31 | 2023 | 1468 | 4.080 |
Why?
| | Reperfusion Injury | 15 | 2019 | 279 | 3.920 |
Why?
| | Complement Factor B | 25 | 2023 | 109 | 3.780 |
Why?
| | Glomerulonephritis | 9 | 2023 | 47 | 3.700 |
Why?
| | Autoimmune Diseases | 10 | 2025 | 460 | 3.150 |
Why?
| | Immunoglobulin M | 10 | 2025 | 289 | 3.070 |
Why?
| | Complement C3 | 25 | 2023 | 209 | 2.900 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 47 | 2.500 |
Why?
| | Acute Kidney Injury | 13 | 2024 | 815 | 2.450 |
Why?
| | Graft Rejection | 10 | 2025 | 624 | 2.290 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 7 | 2025 | 22 | 2.270 |
Why?
| | Kidney Tubules | 8 | 2024 | 117 | 1.870 |
Why?
| | Receptor, Anaphylatoxin C5a | 7 | 2024 | 30 | 1.790 |
Why?
| | Receptors, Complement | 11 | 2022 | 122 | 1.680 |
Why?
| | Lupus Nephritis | 7 | 2021 | 63 | 1.630 |
Why?
| | Antibodies | 4 | 2024 | 410 | 1.560 |
Why?
| | Endothelial Cells | 7 | 2025 | 785 | 1.540 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 10 | 1.520 |
Why?
| | Nephrotic Syndrome | 2 | 2022 | 39 | 1.490 |
Why?
| | Animals | 109 | 2025 | 36940 | 1.480 |
Why?
| | Annexin A2 | 2 | 2025 | 16 | 1.460 |
Why?
| | Mice | 76 | 2025 | 17787 | 1.430 |
Why?
| | Complement C3d | 10 | 2025 | 67 | 1.430 |
Why?
| | Mice, Knockout | 35 | 2025 | 3015 | 1.410 |
Why?
| | Kidney Transplantation | 9 | 2025 | 708 | 1.350 |
Why?
| | Complement C3b | 4 | 2023 | 34 | 1.350 |
Why?
| | Epitopes | 8 | 2023 | 479 | 1.300 |
Why?
| | Inflammation | 16 | 2025 | 2837 | 1.290 |
Why?
| | Kidney Failure, Chronic | 4 | 2025 | 570 | 1.200 |
Why?
| | Disease Models, Animal | 31 | 2025 | 4295 | 1.180 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 42 | 1.160 |
Why?
| | Antibodies, Monoclonal | 17 | 2025 | 1430 | 1.160 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 890 | 1.160 |
Why?
| | Epithelial Cells | 10 | 2024 | 1096 | 1.140 |
Why?
| | Mice, Inbred C57BL | 45 | 2025 | 5757 | 1.110 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 13 | 1.090 |
Why?
| | Contrast Media | 4 | 2018 | 467 | 1.010 |
Why?
| | Complement C5a | 7 | 2024 | 71 | 1.000 |
Why?
| | Glomerulonephritis, Membranoproliferative | 3 | 2023 | 13 | 1.000 |
Why?
| | Humans | 104 | 2025 | 137585 | 0.980 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 20 | 0.970 |
Why?
| | Antibodies, Anticardiolipin | 1 | 2025 | 11 | 0.950 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 20 | 0.940 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 71 | 0.930 |
Why?
| | Delayed Graft Function | 1 | 2025 | 33 | 0.930 |
Why?
| | Infliximab | 1 | 2025 | 111 | 0.910 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 390 | 0.910 |
Why?
| | Organ Transplantation | 2 | 2019 | 250 | 0.890 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 927 | 0.820 |
Why?
| | Biomarkers | 18 | 2025 | 4149 | 0.820 |
Why?
| | Nephritis | 2 | 2013 | 23 | 0.800 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 90 | 0.800 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 242 | 0.790 |
Why?
| | Immunoglobulin G | 12 | 2025 | 893 | 0.780 |
Why?
| | Complement Membrane Attack Complex | 7 | 2025 | 39 | 0.780 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 24 | 0.770 |
Why?
| | Tissue Donors | 1 | 2025 | 425 | 0.750 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3566 | 0.710 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 21 | 0.710 |
Why?
| | Cardiolipins | 1 | 2021 | 85 | 0.700 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 411 | 0.680 |
Why?
| | Otitis Media | 5 | 2016 | 165 | 0.620 |
Why?
| | Cyclosporine | 3 | 2019 | 268 | 0.620 |
Why?
| | Biomedical Research | 2 | 2025 | 692 | 0.610 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 6 | 0.610 |
Why?
| | Vascular System Injuries | 1 | 2019 | 71 | 0.610 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 77 | 0.600 |
Why?
| | Complement Factor D | 1 | 2018 | 30 | 0.580 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 115 | 0.570 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 11 | 0.550 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 804 | 0.550 |
Why?
| | Autoantibodies | 10 | 2023 | 1496 | 0.550 |
Why?
| | Doxorubicin | 4 | 2023 | 362 | 0.540 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 434 | 0.540 |
Why?
| | Transplantation, Homologous | 3 | 2019 | 416 | 0.530 |
Why?
| | B-Lymphocytes | 7 | 2022 | 847 | 0.530 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 362 | 0.520 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 81 | 0.520 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 617 | 0.520 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 86 | 0.500 |
Why?
| | Podocytes | 3 | 2025 | 69 | 0.490 |
Why?
| | Renal Insufficiency | 1 | 2018 | 162 | 0.490 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 169 | 0.470 |
Why?
| | Peptide Fragments | 1 | 2019 | 706 | 0.470 |
Why?
| | Male | 51 | 2025 | 67762 | 0.470 |
Why?
| | Graft Survival | 5 | 2025 | 535 | 0.460 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1272 | 0.450 |
Why?
| | Complement C3a | 4 | 2024 | 42 | 0.450 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 30 | 0.450 |
Why?
| | Pregnancy Complications | 3 | 2018 | 527 | 0.440 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1396 | 0.440 |
Why?
| | Liver Neoplasms | 1 | 2020 | 786 | 0.430 |
Why?
| | Female | 46 | 2025 | 73304 | 0.420 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 530 | 0.420 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 8 | 0.400 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 84 | 0.380 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 259 | 0.380 |
Why?
| | Immunity, Humoral | 1 | 2013 | 116 | 0.380 |
Why?
| | Autoimmunity | 5 | 2022 | 908 | 0.380 |
Why?
| | Liver | 2 | 2020 | 1943 | 0.370 |
Why?
| | Molecular Imaging | 1 | 2012 | 56 | 0.370 |
Why?
| | Complement C1q | 3 | 2014 | 37 | 0.370 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 115 | 0.360 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 852 | 0.360 |
Why?
| | Oxidative Stress | 8 | 2024 | 1317 | 0.350 |
Why?
| | Complement C2 | 2 | 2011 | 7 | 0.350 |
Why?
| | Nanoparticles | 2 | 2013 | 481 | 0.330 |
Why?
| | CD55 Antigens | 3 | 2020 | 30 | 0.330 |
Why?
| | Blotting, Western | 7 | 2016 | 1226 | 0.330 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 273 | 0.330 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 27 | 0.330 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 75 | 0.330 |
Why?
| | Cell Membrane | 4 | 2022 | 738 | 0.330 |
Why?
| | Prognosis | 6 | 2025 | 4030 | 0.320 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 30 | 0.320 |
Why?
| | Disease Susceptibility | 2 | 2020 | 347 | 0.320 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 746 | 0.310 |
Why?
| | Protozoan Proteins | 3 | 1998 | 82 | 0.310 |
Why?
| | Adult | 14 | 2025 | 37929 | 0.300 |
Why?
| | Properdin | 2 | 2020 | 9 | 0.300 |
Why?
| | Diarrhea | 1 | 2009 | 184 | 0.290 |
Why?
| | Antibody Specificity | 2 | 2021 | 189 | 0.290 |
Why?
| | Kidney Function Tests | 2 | 2025 | 160 | 0.290 |
Why?
| | Cytokines | 5 | 2019 | 2085 | 0.290 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.290 |
Why?
| | Signal Transduction | 9 | 2020 | 5079 | 0.280 |
Why?
| | Complement C4 | 5 | 2021 | 28 | 0.280 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 141 | 0.280 |
Why?
| | Uremia | 2 | 2021 | 16 | 0.280 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 70 | 0.280 |
Why?
| | Disease Progression | 6 | 2025 | 2757 | 0.280 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.270 |
Why?
| | Cell Line | 7 | 2025 | 2847 | 0.270 |
Why?
| | Blood Platelets | 2 | 2024 | 408 | 0.270 |
Why?
| | Phagocytosis | 4 | 2023 | 380 | 0.270 |
Why?
| | Chemokines, CXC | 1 | 2007 | 70 | 0.260 |
Why?
| | Adaptive Immunity | 2 | 2019 | 165 | 0.260 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 128 | 0.260 |
Why?
| | Metabolomics | 4 | 2019 | 678 | 0.260 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 127 | 0.260 |
Why?
| | Immunity, Innate | 7 | 2025 | 828 | 0.260 |
Why?
| | Cells, Cultured | 6 | 2019 | 4193 | 0.250 |
Why?
| | Flow Cytometry | 4 | 2022 | 1178 | 0.250 |
Why?
| | Middle Aged | 12 | 2025 | 33479 | 0.250 |
Why?
| | Chemokines | 1 | 2007 | 228 | 0.240 |
Why?
| | Pilot Projects | 3 | 2021 | 1710 | 0.240 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 209 | 0.240 |
Why?
| | Immune System Diseases | 1 | 2006 | 39 | 0.240 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1738 | 0.240 |
Why?
| | Protein Binding | 6 | 2019 | 2224 | 0.240 |
Why?
| | NF-kappa B | 3 | 2016 | 691 | 0.240 |
Why?
| | Organ Specificity | 3 | 2020 | 305 | 0.240 |
Why?
| | Rats | 9 | 2024 | 5647 | 0.230 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 27 | 0.230 |
Why?
| | Biopsy | 3 | 2019 | 1129 | 0.230 |
Why?
| | Caspases | 1 | 2006 | 247 | 0.230 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 25 | 0.230 |
Why?
| | Fetal Death | 1 | 2005 | 55 | 0.230 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 532 | 0.230 |
Why?
| | Macular Degeneration | 3 | 2012 | 164 | 0.220 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 24 | 0.220 |
Why?
| | Platelet Activation | 1 | 2024 | 93 | 0.220 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 433 | 0.220 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 36 | 0.210 |
Why?
| | Child | 11 | 2023 | 21935 | 0.210 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 12 | 0.210 |
Why?
| | Transplant Recipients | 1 | 2025 | 184 | 0.200 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 38 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 92 | 0.200 |
Why?
| | Ischemia | 3 | 2015 | 409 | 0.190 |
Why?
| | Tacrolimus | 2 | 2014 | 199 | 0.190 |
Why?
| | Case-Control Studies | 2 | 2021 | 3556 | 0.190 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 201 | 0.190 |
Why?
| | Allografts | 2 | 2019 | 146 | 0.190 |
Why?
| | CD59 Antigens | 3 | 2011 | 20 | 0.180 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 75 | 0.180 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 24 | 0.180 |
Why?
| | Proteomics | 4 | 2018 | 1111 | 0.180 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 12 | 0.180 |
Why?
| | Myoglobin | 1 | 2021 | 13 | 0.180 |
Why?
| | Apoptosis | 2 | 2011 | 2553 | 0.180 |
Why?
| | Immune System | 1 | 2022 | 177 | 0.180 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 27 | 0.180 |
Why?
| | Glutamic Acid | 1 | 2023 | 246 | 0.170 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 465 | 0.170 |
Why?
| | Proteinuria | 3 | 2012 | 97 | 0.170 |
Why?
| | Frozen Sections | 1 | 2021 | 26 | 0.170 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 56 | 0.170 |
Why?
| | Paraffin Embedding | 1 | 2021 | 32 | 0.170 |
Why?
| | Hypertension, Pulmonary | 2 | 2024 | 1910 | 0.170 |
Why?
| | Albuminuria | 2 | 2015 | 185 | 0.170 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 20 | 0.170 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 23 | 0.170 |
Why?
| | Formaldehyde | 1 | 2021 | 63 | 0.170 |
Why?
| | Staining and Labeling | 1 | 2021 | 150 | 0.170 |
Why?
| | Dendritic Cells | 2 | 2022 | 483 | 0.170 |
Why?
| | Aged | 8 | 2021 | 23961 | 0.160 |
Why?
| | Up-Regulation | 3 | 2019 | 843 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 146 | 0.160 |
Why?
| | Lung | 6 | 2024 | 4060 | 0.160 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 10 | 0.160 |
Why?
| | Treatment Outcome | 3 | 2021 | 10811 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 545 | 0.160 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 194 | 0.150 |
Why?
| | Urinalysis | 1 | 2019 | 77 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 179 | 0.150 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1996 | 0.150 |
Why?
| | Critical Illness | 2 | 2023 | 811 | 0.150 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 145 | 0.150 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.150 |
Why?
| | Sepsis | 2 | 2016 | 617 | 0.150 |
Why?
| | North America | 1 | 2019 | 313 | 0.150 |
Why?
| | Complement C5 | 3 | 2020 | 81 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 976 | 0.140 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 15 | 0.140 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2828 | 0.140 |
Why?
| | Granulocytes | 2 | 2016 | 80 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2020 | 193 | 0.140 |
Why?
| | Organelles | 1 | 1998 | 58 | 0.140 |
Why?
| | HLA Antigens | 1 | 2019 | 240 | 0.140 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.140 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.140 |
Why?
| | Erythrocytes | 2 | 2020 | 700 | 0.140 |
Why?
| | Gene Expression | 6 | 2017 | 1502 | 0.140 |
Why?
| | Cyclophilins | 1 | 2017 | 40 | 0.140 |
Why?
| | Brain Injuries | 3 | 2007 | 494 | 0.130 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 15 | 0.130 |
Why?
| | Brachial Artery | 1 | 2018 | 205 | 0.130 |
Why?
| | Adolescent | 7 | 2021 | 21513 | 0.130 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.130 |
Why?
| | Liraglutide | 1 | 2016 | 30 | 0.130 |
Why?
| | Cell Differentiation | 2 | 2022 | 1991 | 0.130 |
Why?
| | Interferon-beta | 2 | 2007 | 92 | 0.130 |
Why?
| | Bleomycin | 1 | 2018 | 248 | 0.130 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 886 | 0.130 |
Why?
| | Cell Aggregation | 1 | 2016 | 26 | 0.130 |
Why?
| | Sulfonylurea Compounds | 1 | 2016 | 48 | 0.130 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 147 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 73 | 0.130 |
Why?
| | Insulin, Long-Acting | 1 | 2016 | 63 | 0.130 |
Why?
| | Ear, Middle | 3 | 2012 | 85 | 0.120 |
Why?
| | Phenols | 1 | 2017 | 99 | 0.120 |
Why?
| | Tuberculosis | 1 | 2019 | 279 | 0.120 |
Why?
| | Collagen Type VII | 3 | 2018 | 28 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1050 | 0.120 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.120 |
Why?
| | Blood Pressure | 1 | 2003 | 1786 | 0.120 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 314 | 0.120 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5131 | 0.120 |
Why?
| | Mitochondria | 2 | 2024 | 948 | 0.120 |
Why?
| | Interferon-alpha | 2 | 2007 | 198 | 0.120 |
Why?
| | Macrophages | 3 | 2013 | 1547 | 0.120 |
Why?
| | Carboxypeptidases | 1 | 2015 | 13 | 0.120 |
Why?
| | Mucin-5B | 1 | 2018 | 224 | 0.120 |
Why?
| | Immunoprecipitation | 1 | 2016 | 155 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 692 | 0.120 |
Why?
| | Prospective Studies | 4 | 2023 | 7604 | 0.120 |
Why?
| | Inflammation Mediators | 3 | 2019 | 513 | 0.120 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 28 | 0.120 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.120 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 14 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2010 | 1316 | 0.120 |
Why?
| | Vaccinia virus | 1 | 2015 | 43 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.120 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 6 | 0.120 |
Why?
| | Vasodilation | 1 | 2018 | 499 | 0.110 |
Why?
| | Ultrasonography | 1 | 2018 | 759 | 0.110 |
Why?
| | Fibroblasts | 1 | 2020 | 996 | 0.110 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 105 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1353 | 0.110 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.110 |
Why?
| | Eustachian Tube | 1 | 2014 | 8 | 0.110 |
Why?
| | Edema | 1 | 2015 | 130 | 0.110 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 188 | 0.110 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.110 |
Why?
| | Hypertension | 1 | 2003 | 1295 | 0.110 |
Why?
| | Models, Immunological | 2 | 2012 | 100 | 0.110 |
Why?
| | Immunoglobulins | 2 | 2020 | 171 | 0.110 |
Why?
| | Mast Cells | 1 | 2015 | 147 | 0.110 |
Why?
| | Neutrophils | 2 | 2013 | 1238 | 0.110 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.100 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 67 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 332 | 0.100 |
Why?
| | Cricetulus | 2 | 2010 | 109 | 0.100 |
Why?
| | CHO Cells | 2 | 2010 | 161 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 117 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 417 | 0.100 |
Why?
| | Cricetinae | 2 | 2010 | 289 | 0.100 |
Why?
| | Serum | 1 | 2013 | 59 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1060 | 0.100 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 87 | 0.100 |
Why?
| | Acute Disease | 3 | 2014 | 1007 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1916 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 991 | 0.100 |
Why?
| | Metformin | 1 | 2016 | 331 | 0.100 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 167 | 0.100 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 135 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 36 | 0.100 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1142 | 0.100 |
Why?
| | Amino Acids | 1 | 2016 | 497 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 391 | 0.100 |
Why?
| | Acute Lung Injury | 1 | 2015 | 287 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2016 | 739 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 68 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 396 | 0.100 |
Why?
| | Rhadinovirus | 1 | 2012 | 20 | 0.090 |
Why?
| | Skin | 2 | 2015 | 752 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2013 | 218 | 0.090 |
Why?
| | Sirolimus | 1 | 2014 | 276 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 665 | 0.090 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 49 | 0.090 |
Why?
| | Rituximab | 1 | 2013 | 176 | 0.090 |
Why?
| | Pregnancy | 4 | 2018 | 6763 | 0.090 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 526 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1091 | 0.090 |
Why?
| | Extracellular Fluid | 1 | 2011 | 31 | 0.090 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 111 | 0.090 |
Why?
| | Spleen | 1 | 2013 | 514 | 0.090 |
Why?
| | Risk Factors | 1 | 2025 | 10388 | 0.090 |
Why?
| | Tissue Distribution | 3 | 2019 | 332 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 147 | 0.090 |
Why?
| | Plasma Exchange | 1 | 2010 | 14 | 0.090 |
Why?
| | Down-Regulation | 4 | 2020 | 657 | 0.090 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 657 | 0.090 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 124 | 0.080 |
Why?
| | Blister | 2 | 2008 | 41 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 940 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2015 | 956 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1483 | 0.080 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 36 | 0.080 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 13 | 0.080 |
Why?
| | Opsonin Proteins | 1 | 2010 | 25 | 0.080 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 120 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 84 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 53 | 0.080 |
Why?
| | Microbial Viability | 1 | 2010 | 91 | 0.080 |
Why?
| | Osteoarthritis | 1 | 2011 | 185 | 0.080 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 364 | 0.080 |
Why?
| | Antibody Formation | 1 | 2010 | 298 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6828 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2010 | 226 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 402 | 0.080 |
Why?
| | Image Enhancement | 1 | 2010 | 190 | 0.080 |
Why?
| | Allergens | 1 | 2011 | 409 | 0.070 |
Why?
| | RNA, Messenger | 6 | 2022 | 2833 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2691 | 0.070 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1208 | 0.070 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 15 | 0.070 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.070 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 34 | 0.070 |
Why?
| | Hemolysis | 2 | 2020 | 206 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 69 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1291 | 0.070 |
Why?
| | Bacteremia | 1 | 2010 | 214 | 0.070 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 43 | 0.070 |
Why?
| | Binding Sites | 3 | 2016 | 1303 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1066 | 0.070 |
Why?
| | Neurons | 2 | 2006 | 1590 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 76 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2426 | 0.070 |
Why?
| | Young Adult | 2 | 2021 | 13209 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1774 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 2017 | 534 | 0.060 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 188 | 0.060 |
Why?
| | Poly I-C | 1 | 2006 | 63 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2006 | 90 | 0.060 |
Why?
| | Leukocytes | 1 | 2008 | 311 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 58 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 69 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 154 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 169 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 435 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 752 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 9 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2167 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 915 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2486 | 0.060 |
Why?
| | Basement Membrane | 1 | 2005 | 35 | 0.060 |
Why?
| | Placental Insufficiency | 1 | 2006 | 116 | 0.060 |
Why?
| | Random Allocation | 1 | 2006 | 353 | 0.060 |
Why?
| | Probability | 1 | 2006 | 304 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 597 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 162 | 0.060 |
Why?
| | Aristolochic Acids | 1 | 2024 | 1 | 0.060 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 131 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3958 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2005 | 62 | 0.060 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2007 | 313 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2526 | 0.050 |
Why?
| | Schistosomiasis | 1 | 2024 | 47 | 0.050 |
Why?
| | Brain | 2 | 2006 | 2668 | 0.050 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 185 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3295 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 452 | 0.050 |
Why?
| | Lung Injury | 1 | 2006 | 219 | 0.050 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 402 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1164 | 0.050 |
Why?
| | Drinking Behavior | 1 | 2003 | 10 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 385 | 0.050 |
Why?
| | Compulsive Behavior | 1 | 2003 | 6 | 0.050 |
Why?
| | Myocardium | 1 | 2009 | 1002 | 0.050 |
Why?
| | Annexins | 1 | 2023 | 3 | 0.050 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 25 | 0.050 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 34 | 0.050 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Folic Acid | 1 | 2024 | 186 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 51 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 54 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 375 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 224 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 311 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 233 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2189 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 72 | 0.050 |
Why?
| | Drug Combinations | 2 | 2016 | 343 | 0.050 |
Why?
| | Energy Metabolism | 2 | 2019 | 922 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 160 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 217 | 0.050 |
Why?
| | Neutralization Tests | 2 | 2015 | 75 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 771 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2531 | 0.050 |
Why?
| | HLA-D Antigens | 1 | 2022 | 34 | 0.050 |
Why?
| | Ubiquitination | 1 | 2022 | 102 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 269 | 0.050 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 79 | 0.040 |
Why?
| | Phospholipase D | 1 | 2020 | 9 | 0.040 |
Why?
| | Cholecalciferol | 1 | 2021 | 60 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 565 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2022 | 218 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 33 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 175 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2139 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 145 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 367 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 394 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 103 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 967 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 622 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 107 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 22 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 44 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 88 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 152 | 0.040 |
Why?
| | Child, Preschool | 2 | 2015 | 11074 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 195 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 652 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 308 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3412 | 0.040 |
Why?
| | Brefeldin A | 1 | 1998 | 10 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 181 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 372 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1998 | 52 | 0.040 |
Why?
| | Cyclopentanes | 1 | 1998 | 19 | 0.040 |
Why?
| | Immunity, Active | 1 | 1998 | 10 | 0.040 |
Why?
| | Aotidae | 1 | 1998 | 7 | 0.040 |
Why?
| | A549 Cells | 1 | 2018 | 66 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 27 | 0.040 |
Why?
| | Parasitemia | 1 | 1998 | 13 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 47 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 409 | 0.040 |
Why?
| | Macrolides | 1 | 1998 | 65 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 69 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 397 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 664 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 385 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 152 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 98 | 0.030 |
Why?
| | Germinal Center | 1 | 2017 | 58 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 185 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 204 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 420 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1242 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 98 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 77 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 20 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 827 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 215 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 110 | 0.030 |
Why?
| | Infant | 1 | 2009 | 9465 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 319 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 151 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 34 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 23 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 172 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 65 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 69 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 26 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 233 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 239 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 216 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 806 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 265 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 872 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 643 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 33 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 5 | 0.030 |
Why?
| | Pyridones | 1 | 2015 | 168 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1250 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 636 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 298 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 2071 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2900 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 382 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 99 | 0.020 |
Why?
| | International Cooperation | 1 | 2013 | 198 | 0.020 |
Why?
| | Complement C4b-Binding Protein | 1 | 2012 | 3 | 0.020 |
Why?
| | Coinfection | 1 | 2014 | 137 | 0.020 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2111 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 114 | 0.020 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 148 | 0.020 |
Why?
| | Hypoxia | 1 | 2020 | 1112 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 391 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 79 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 85 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1020 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 24 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 68 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2016 | 445 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 1993 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 365 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 182 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 183 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 363 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 455 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 171 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 171 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 625 | 0.020 |
Why?
| | Joints | 1 | 2011 | 105 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 321 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 451 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 275 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 103 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 376 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 188 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 151 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 313 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 611 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 307 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 212 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1325 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 476 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 213 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 499 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 430 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1062 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 26 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1092 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 49 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 861 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1809 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 161 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 86 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 76 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 23 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 891 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 149 | 0.020 |
Why?
| | Cattle | 1 | 2009 | 984 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 358 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 767 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 57 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2181 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 18 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 71 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 2186 | 0.020 |
Why?
| | Vaccination | 1 | 2015 | 1381 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 52 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 445 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 48 | 0.020 |
Why?
| | fas Receptor | 1 | 2006 | 95 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 71 | 0.020 |
Why?
| | Trachea | 1 | 2007 | 237 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 106 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 232 | 0.020 |
Why?
| | Synovial Membrane | 1 | 2006 | 117 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5472 | 0.010 |
Why?
| | Models, Molecular | 1 | 2010 | 1570 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 302 | 0.010 |
Why?
| | Cell Death | 1 | 2006 | 374 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3284 | 0.010 |
Why?
| | Swine | 1 | 2006 | 775 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3196 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 20 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 563 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 35 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 309 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 985 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 171 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1120 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 501 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 778 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 94 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1783 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2607 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2057 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1046 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 500 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2671 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 750 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 24 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 2295 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 167 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 392 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|